EPAS1 and cancer: Given that HIF-2α is an important transcription factor in cancer progression and leads to poor prognosis69,70, these findings suggest that targeting HIF-2α might be an effective therapeutic strategy by inhibiting glutamine metabolism in these notorious cancers.